{"gene":"ATXN2L","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":2015,"finding":"ATXN2L is asymmetrically dimethylated in vivo and associates with protein arginine-N-methyltransferase 1 (PRMT1). Inhibition of arginine methylation alters the nuclear localization of ATXN2L, but neither mutation of the arginine-glycine-rich motifs nor methylation inhibition affects ATXN2L localization to stress granules, indicating that arginine methylation by PRMT1 controls ATXN2L nuclear (but not stress granule) localization.","method":"Co-immunoprecipitation, methylation inhibition assays, site-directed mutagenesis of RG motifs, immunofluorescence localization","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2-3 — reciprocal association shown by Co-IP, functional consequence of methylation on localization demonstrated, single lab","pmids":["25748791"],"is_preprint":false},{"year":2017,"finding":"A chromosomal translocation t(9;13;16) in cutaneous CD4+ T-cell lymphoma fuses ATXN2L (chromosome 16p11) to JAK2 (chromosome 9p24), producing an ATXN2L–JAK2 chimeric protein that retains all ATXN2L domains fused to the JAK2 catalytic tyrosine kinase domain, predicted to cause constitutive JAK-STAT pathway activation.","method":"RNA sequencing, RT-PCR, Sanger sequencing of fusion transcript","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — fusion transcript verified by orthogonal sequencing methods; functional consequence inferred by analogy to other JAK2 fusions, single case study","pmids":["29262599"],"is_preprint":false},{"year":2019,"finding":"ATXN2L promotes gastric cancer cell migration and invasion via epithelial-to-mesenchymal transition and confers intrinsic and acquired resistance to oxaliplatin by reducing reactive oxygen species and apoptosis. EGF upregulates ATXN2L expression through PI3K/Akt signaling, and oxaliplatin treatment itself induces ATXN2L expression and stress granule assembly.","method":"siRNA knockdown, invasion/migration assays, ROS measurement, apoptosis assays, generation of oxaliplatin-resistant cell strains, pharmacological PI3K/Akt inhibition, EGFR blocking","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2-3 — multiple functional assays in cell lines with defined phenotypic readouts, single lab","pmids":["30787271"],"is_preprint":false},{"year":2020,"finding":"ATXN2L is essential for embryonic development: homozygous CRISPR/Cas9 deletion of Atxn2l exons 5–8 in mice causes mid-gestational lethality with brain lamination defects and apoptosis, while heterozygotes are phenotypically normal over 12 months. ATXN2L-null mouse embryonic fibroblasts show increased multinucleated giant cells. ATXN2L and its paralog ATXN2 do not regulate each other's expression levels.","method":"CRISPR/Cas9 knockout mice, embryo histology, MEF culture, western blotting, locomotor assessment of heterozygotes","journal":"International journal of molecular sciences","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic KO with strong embryonic lethality phenotype, histological and cellular characterization, replicated across developmental timepoints","pmids":["32698485"],"is_preprint":false},{"year":2022,"finding":"HDAC3 interacts with ATXN2L and through this interaction antagonizes the NRG1-ErbB2-PI3K-AKT signaling axis in Schwann cells to suppress myelination. Inhibiting HDAC3's recruitment of ATXN2L (by jatrorrhizine treatment) restores myelination in diabetic peripheral neuropathy mice.","method":"LC-MS/MS proteomics, co-immunoprecipitation, in vivo db/db mouse model, nerve histopathology, nerve conduction velocity measurement","journal":"Phytotherapy research","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP confirms HDAC3–ATXN2L interaction, in vivo phenotypic rescue data, single lab","pmids":["36218239"],"is_preprint":false},{"year":2025,"finding":"ATXN2L's primary interactor is NUFIP2, with additional strong associations to RNA-binding proteins (PABPN1, MCRIP2, RBMS1, LARP1, PTBP1, FMR1, RPS20, FUBP3, MBNL2, ZMAT3, SFPQ, CSDE1, HNRNPK, HNRNPDL) and actin complex components (SYNE2, LMOD1, ACTA2, FYB, GOLGA3). ATXN2L absence leads to depletion of NUFIP2 and SYNE2 in fibroblasts. Oxidative stress increases HNRNPK but decreases SYNE2 association with ATXN2L, reflecting stress granule relocalization. In an SCA2 mouse model (Atxn2-CAG100-KnockIn), NUFIP2 homodimers and SYNE1 accumulate during ATXN2 aggregation, suggesting ATXN2L sequestration contributes to disease.","method":"Co-immunoprecipitation in WT and ATXN2L-null MEFs, mass spectrometry proteome profiling, SCA2 knock-in mouse spinal cord analysis","journal":"Neurobiology of disease","confidence":"High","confidence_rationale":"Tier 1-2 — systematic Co-IP combined with proteome-wide MS profiling in null cells and disease mouse model; multiple orthogonal methods","pmids":["40220918"],"is_preprint":false},{"year":2025,"finding":"Conditional deletion of ATXN2L Lsm/LsmAD/PAM2 domains (exons 10–17) in CamK2a+ frontal cortex neurons reduces spontaneous horizontal movement without causing neuronal death, and proteome profiling reveals dysregulation enriched in the alternative splicing pathway, suggesting ATXN2L's Lsm/LsmAD domains contribute to splice regulation from a perinuclear location.","method":"Conditional CamK2a-CreERT2 × floxed ATXN2L mice, tamoxifen induction, open-field locomotor testing, global proteome profiling by mass spectrometry","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 — domain-specific conditional KO with behavioral and proteome-level functional readouts, single lab","pmids":["41090760"],"is_preprint":false},{"year":2025,"finding":"ATXN2L undergoes liquid-liquid phase separation (LLPS) to form cytoplasmic granules that recruit eukaryotic initiation factors (eIFs) and promote mRNA translation of targets such as ADAM9 (ADAM metallopeptidase domain 9), thereby driving hepatocellular carcinoma progression. Co-localization with stress granules further enhances ATXN2L granule-mediated ADAM9 translation. Knockout of Atxn2l in mice suppresses HCC progression.","method":"LLPS assay, granule imaging, eIF co-localization, ADAM9 translation assays, ATXN2L knockdown/knockout in cell lines and mice, in vivo HCC models","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic LLPS characterization with in vitro and in vivo validation, single lab","pmids":["41273724"],"is_preprint":false},{"year":2025,"finding":"ATXN2L-containing stress granule proteins (including ATXN2L itself) associate with MEWNG-rich proteins translated from cytoplasmic HSATIII lncRNAs during thermal stress recovery, placing ATXN2L in a cytoplasmic granule complex that also contains HSPA8 and ZC3HAV1.","method":"Proximity labeling, co-immunoprecipitation, fluorescence imaging, ribosome profiling (preprint)","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 3 — preprint; ATXN2L is one component among many, single lab, not yet peer-reviewed","pmids":[],"is_preprint":true}],"current_model":"ATXN2L is a perinuclear RNA-binding protein with Lsm/LsmAD/PAM2 domains that is essential for embryonic development, undergoes liquid-liquid phase separation to form granules that promote mRNA translation, participates in RNA quality control and alternative splicing, is asymmetrically dimethylated by PRMT1 (controlling its nuclear but not stress-granule localization), primarily interacts with NUFIP2 and a broad network of RNA-binding proteins and actin complex components, can be oncogenically activated via ATXN2L–JAK2 chromosomal fusion, and is upregulated downstream of EGF/PI3K/Akt signaling to promote cancer cell invasiveness and chemoresistance."},"narrative":{"teleology":[{"year":2015,"claim":"The first post-translational regulatory mechanism for ATXN2L was defined: PRMT1-mediated asymmetric arginine dimethylation controls ATXN2L nuclear localization but is dispensable for its recruitment to stress granules, establishing that distinct signals govern ATXN2L's dual compartmentalization.","evidence":"Co-IP, methylation inhibition, RG-motif mutagenesis, and immunofluorescence in cultured cells","pmids":["25748791"],"confidence":"Medium","gaps":["Nuclear functions of ATXN2L remain undefined","Whether other PRMTs modify ATXN2L is untested","Single-lab observation without independent replication"]},{"year":2017,"claim":"Discovery of an ATXN2L–JAK2 fusion transcript in cutaneous T-cell lymphoma demonstrated that ATXN2L can serve as a 5′ partner in oncogenic chromosomal rearrangements, analogous to other JAK2 fusions that constitutively activate JAK-STAT signaling.","evidence":"RNA-seq, RT-PCR, and Sanger sequencing of a t(9;13;16) translocation in a single patient","pmids":["29262599"],"confidence":"Medium","gaps":["Constitutive kinase activity of the fusion was inferred by analogy, not directly demonstrated","Single case report; frequency of ATXN2L–JAK2 fusions unknown","Mechanism by which ATXN2L domains contribute to oncogenic activity is uncharacterized"]},{"year":2019,"claim":"ATXN2L was placed in the EGF/PI3K/Akt signaling axis as a downstream effector that promotes epithelial–mesenchymal transition, cell invasion, and chemoresistance in gastric cancer, revealing a cancer-relevant function beyond its RNA-binding roles.","evidence":"siRNA knockdown, invasion/migration assays, ROS and apoptosis measurement, oxaliplatin-resistant cell generation, PI3K/Akt inhibition in gastric cancer cell lines","pmids":["30787271"],"confidence":"Medium","gaps":["Direct transcriptional or post-transcriptional targets mediating chemoresistance are not identified","In vivo validation in tumor models was not performed","Mechanism linking stress granule assembly to oxaliplatin resistance is unclear"]},{"year":2020,"claim":"Genetic ablation of Atxn2l in mice established its essentiality for embryonic development, with homozygous loss causing mid-gestational lethality, brain lamination defects, and increased multinucleated cell formation, distinguishing it functionally from its paralog ATXN2.","evidence":"CRISPR/Cas9 whole-body knockout mice, embryo histology across developmental stages, MEF culture, western blotting","pmids":["32698485"],"confidence":"High","gaps":["Molecular pathways driving embryonic lethality are not delineated","Cell-type-specific requirements during development are unknown","Cause of multinucleated cell phenotype (cytokinesis failure vs. cell fusion) is unresolved"]},{"year":2022,"claim":"The HDAC3–ATXN2L interaction was identified as a negative regulator of NRG1-ErbB2-PI3K-AKT myelination signaling in Schwann cells, placing ATXN2L in a chromatin-associated regulatory complex relevant to peripheral neuropathy.","evidence":"LC-MS/MS proteomics, Co-IP, in vivo db/db diabetic mouse model with nerve histopathology and conduction velocity","pmids":["36218239"],"confidence":"Medium","gaps":["Whether ATXN2L acts as an HDAC3 co-repressor or scaffold is not determined","Direct gene targets of the HDAC3–ATXN2L complex are uncharacterized","Single-lab finding without independent confirmation"]},{"year":2025,"claim":"Systematic interactome mapping identified NUFIP2 as ATXN2L's primary binding partner and revealed a broad network of RNA-binding proteins and actin complex components; stress-dependent remodeling of these interactions linked ATXN2L to stress granule biology and, in an SCA2 mouse model, suggested that ATXN2 aggregation sequesters ATXN2L-associated factors.","evidence":"Co-IP/MS in WT and ATXN2L-null MEFs, SCA2 Atxn2-CAG100-KnockIn mouse spinal cord proteomics","pmids":["40220918"],"confidence":"High","gaps":["Direct RNA targets bound by ATXN2L are not defined","Whether ATXN2L sequestration causally contributes to SCA2 pathogenesis is unproven","Structural basis of the ATXN2L–NUFIP2 interaction is unknown"]},{"year":2025,"claim":"Conditional deletion of ATXN2L's Lsm/LsmAD/PAM2 domains in cortical neurons demonstrated a requirement for these domains in normal locomotor behavior and implicated ATXN2L in alternative splicing regulation based on proteome-level changes.","evidence":"CamK2a-CreERT2 conditional KO mice, open-field locomotor testing, global proteome profiling by MS","pmids":["41090760"],"confidence":"Medium","gaps":["Specific splice targets are not identified","Contribution of individual domains (Lsm vs. PAM2) was not dissected","Only proteome-level enrichment inferred; direct splicing assays were not performed"]},{"year":2025,"claim":"ATXN2L was shown to undergo liquid–liquid phase separation forming cytoplasmic granules that recruit eIF complexes to promote mRNA translation of specific targets such as ADAM9, directly linking ATXN2L's condensation behavior to translational control and hepatocellular carcinoma progression.","evidence":"LLPS assays, granule imaging with eIF co-localization, ADAM9 translation assays, ATXN2L KO in mice with in vivo HCC models","pmids":["41273724"],"confidence":"Medium","gaps":["Transcriptome-wide identification of ATXN2L-granule-regulated mRNAs is lacking","Biophysical determinants of phase separation (IDRs, multivalency) not fully mapped","Whether LLPS is required for all ATXN2L translational functions or specific subsets is unclear"]},{"year":null,"claim":"Key open questions include the full repertoire of direct RNA targets, the structural basis of ATXN2L phase separation and NUFIP2 binding, the mechanism by which ATXN2L loss causes embryonic lethality, and whether ATXN2L sequestration is a causal contributor to SCA2 neurodegeneration.","evidence":"","pmids":[],"confidence":"High","gaps":["No CLIP-seq or equivalent data defining direct RNA targets","No high-resolution structure of ATXN2L or its complexes","Causal role of ATXN2L in SCA2 pathogenesis untested by genetic rescue"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[5,6,7]},{"term_id":"GO:0045182","term_label":"translation regulator activity","supporting_discovery_ids":[7]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,7,8]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[5,6,7]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[6,7]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,4]}],"complexes":[],"partners":["NUFIP2","PRMT1","HDAC3","PABPN1","LARP1","FMR1","SYNE2","HNRNPK"],"other_free_text":[]},"mechanistic_narrative":"ATXN2L is a perinuclear RNA-binding protein containing Lsm, LsmAD, and PAM2 domains that is essential for mammalian embryonic development, with homozygous loss causing mid-gestational lethality with brain lamination defects [PMID:32698485]. ATXN2L undergoes liquid–liquid phase separation to form cytoplasmic granules that recruit eukaryotic initiation factors and promote mRNA translation, and it participates in alternative splicing regulation through its Lsm/LsmAD domains [PMID:41273724, PMID:41090760]. Its primary physical interactor is NUFIP2, and it associates with a broad network of RNA-binding proteins and actin complex components; oxidative stress dynamically remodels these interactions as ATXN2L relocalizes to stress granules [PMID:40220918]. ATXN2L is asymmetrically dimethylated by PRMT1, which controls its nuclear but not stress-granule localization, and its expression is upregulated by EGF/PI3K/Akt signaling to promote cancer cell invasiveness and chemoresistance [PMID:25748791, PMID:30787271]."},"prefetch_data":{"uniprot":{"accession":"Q8WWM7","full_name":"Ataxin-2-like protein","aliases":["Ataxin-2 domain protein","Ataxin-2-related protein"],"length_aa":1075,"mass_kda":113.4,"function":"Involved in the regulation of stress granule and P-body formation","subcellular_location":"Membrane; Cytoplasm; Nucleus speckle; Cytoplasmic granule","url":"https://www.uniprot.org/uniprotkb/Q8WWM7/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ATXN2L","classification":"Not Classified","n_dependent_lines":57,"n_total_lines":1208,"dependency_fraction":0.04718543046357616},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000168488","cell_line_id":"CID001509","localizations":[{"compartment":"cytoplasmic","grade":3}],"interactors":[{"gene":"FAM195B","stoichiometry":10.0},{"gene":"DDX6","stoichiometry":10.0},{"gene":"LSM12","stoichiometry":0.2},{"gene":"NUFIP2","stoichiometry":0.2},{"gene":"SLMAP","stoichiometry":0.2},{"gene":"PABPC4","stoichiometry":0.2},{"gene":"PABPC1;PABPC3","stoichiometry":0.2},{"gene":"RCBTB2","stoichiometry":0.2},{"gene":"CAPZB","stoichiometry":0.2},{"gene":"G3BP2","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001509","total_profiled":1310},"omim":[{"mim_id":"607931","title":"ATAXIN 2-LIKE; ATXN2L","url":"https://www.omim.org/entry/607931"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Cytosol","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ATXN2L"},"hgnc":{"alias_symbol":["A2lp","A2D"],"prev_symbol":[]},"alphafold":{"accession":"Q8WWM7","domains":[{"cath_id":"2.30.30.100","chopping":"117-206","consensus_level":"high","plddt":88.2149,"start":117,"end":206},{"cath_id":"-","chopping":"250-281","consensus_level":"medium","plddt":85.9928,"start":250,"end":281},{"cath_id":"-","chopping":"285-317","consensus_level":"medium","plddt":88.0,"start":285,"end":317}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8WWM7","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8WWM7-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8WWM7-F1-predicted_aligned_error_v6.png","plddt_mean":48.53},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ATXN2L","jax_strain_url":"https://www.jax.org/strain/search?query=ATXN2L"},"sequence":{"accession":"Q8WWM7","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8WWM7.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8WWM7/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8WWM7"}},"corpus_meta":[{"pmid":"30787271","id":"PMC_30787271","title":"ATXN2L upregulated by epidermal growth factor promotes gastric cancer cell invasiveness and oxaliplatin resistance.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30787271","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32698485","id":"PMC_32698485","title":"Mid-Gestation lethality of Atxn2l-Ablated Mice.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32698485","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29262599","id":"PMC_29262599","title":"Fusion of the genes ataxin 2 like, ATXN2L, and Janus kinase 2, JAK2, in cutaneous CD4 positive T-cell lymphoma.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29262599","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25748791","id":"PMC_25748791","title":"PRMT1-mediated arginine methylation controls ATXN2L localization.","date":"2015","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/25748791","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36218239","id":"PMC_36218239","title":"Jatrorrhizine ameliorates Schwann cell myelination via inhibiting HDAC3 ability to recruit Atxn2l for regulating the NRG1-ErbB2-PI3K-AKT pathway in diabetic peripheral neuropathy mice.","date":"2022","source":"Phytotherapy research : PTR","url":"https://pubmed.ncbi.nlm.nih.gov/36218239","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40220918","id":"PMC_40220918","title":"ATXN2L primarily interacts with NUFIP2, the absence of ATXN2L results in NUFIP2 depletion, and the ATXN2-polyQ expansion triggers NUFIP2 accumulation.","date":"2025","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/40220918","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35513260","id":"PMC_35513260","title":"From the comparative study of a circRNA originating from an mammalian ATXN2L intron to understanding the genesis of intron lariat-derived circRNAs.","date":"2022","source":"Biochimica et biophysica acta. Gene regulatory mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/35513260","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40533826","id":"PMC_40533826","title":"Exosomal FOXL1 from bone marrow mesenchymal stem cells activates the METTL3/ATXN2L pathway to ameliorate high glucose-induced human retinal microvascular endothelial cell injury.","date":"2025","source":"Diabetology & metabolic syndrome","url":"https://pubmed.ncbi.nlm.nih.gov/40533826","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41090760","id":"PMC_41090760","title":"Conditional ATXN2L-Null in Adult Frontal Cortex CamK2a+ Neurons Does Not Cause Cell Death but Restricts Spontaneous Mobility and Affects the Alternative Splicing Pathway.","date":"2025","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/41090760","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41273724","id":"PMC_41273724","title":"Liquid-liquid phase separation of ATXN2L enhances mRNA translation in hepatocellular carcinoma.","date":"2025","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/41273724","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39820928","id":"PMC_39820928","title":"Circ-NMNAT1 Drives Tumor Progression in Bladder Cancer by Modulating the miR-370-3p/ATXN2L Axis.","date":"2025","source":"Applied biochemistry and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/39820928","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41688673","id":"PMC_41688673","title":"Complete remission of relapsed ATXN2L::JAK2 fusion positive anaplastic large cell lymphoma following ruxolitinib monotherapy in a child.","date":"2026","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41688673","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.11.12.688122","title":"Cytoplasmic roles of HSATIII RNAs in RNA granule assembly and production of actin cytoskeleton-associated repeat-containing proteins","date":"2025-11-13","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.12.688122","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"17081983","id":"PMC_17081983","title":"Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/17081983","citation_count":2861,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20935630","id":"PMC_20935630","title":"Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20935630","citation_count":2251,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22658674","id":"PMC_22658674","title":"Insights into RNA biology from an atlas of mammalian mRNA-binding proteins.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22658674","citation_count":1718,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16964243","id":"PMC_16964243","title":"A probability-based approach for high-throughput protein phosphorylation analysis and site localization.","date":"2006","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/16964243","citation_count":1336,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19615732","id":"PMC_19615732","title":"Defining the human deubiquitinating enzyme interaction landscape.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19615732","citation_count":1282,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26777405","id":"PMC_26777405","title":"ATPase-Modulated Stress Granules Contain a Diverse Proteome and Substructure.","date":"2016","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26777405","citation_count":1233,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15302935","id":"PMC_15302935","title":"Large-scale characterization of HeLa cell nuclear phosphoproteins.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15302935","citation_count":1159,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22681889","id":"PMC_22681889","title":"The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts.","date":"2012","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/22681889","citation_count":973,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8896555","id":"PMC_8896555","title":"Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2.","date":"1996","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8896555","citation_count":967,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16713569","id":"PMC_16713569","title":"A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16713569","citation_count":610,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29395067","id":"PMC_29395067","title":"High-Density Proximity Mapping Reveals the Subcellular Organization of mRNA-Associated Granules and Bodies.","date":"2018","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/29395067","citation_count":580,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28302793","id":"PMC_28302793","title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15.","date":"2017","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/28302793","citation_count":533,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17110338","id":"PMC_17110338","title":"Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/17110338","citation_count":517,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23722424","id":"PMC_23722424","title":"GWAS of 126,559 individuals identifies genetic variants associated with educational attainment.","date":"2013","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/23722424","citation_count":503,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20020773","id":"PMC_20020773","title":"Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery.","date":"2010","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/20020773","citation_count":422,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19915574","id":"PMC_19915574","title":"Common variants at five new loci associated with early-onset inflammatory bowel disease.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19915574","citation_count":394,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16009940","id":"PMC_16009940","title":"Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16009940","citation_count":383,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15782174","id":"PMC_15782174","title":"Identifying and quantifying in vivo methylation sites by heavy methyl SILAC.","date":"2004","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/15782174","citation_count":364,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34079125","id":"PMC_34079125","title":"A proximity-dependent biotinylation map of a human cell.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34079125","citation_count":339,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":8421,"output_tokens":2244,"usd":0.029462},"stage2":{"model":"claude-opus-4-6","input_tokens":5545,"output_tokens":2691,"usd":0.1425},"total_usd":0.368346,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":19938,"output_tokens":2633,"usd":0.049654},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":6179,"output_tokens":2677,"usd":0.14673}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2015,\n      \"finding\": \"ATXN2L is asymmetrically dimethylated in vivo by PRMT1; ATXN2L physically associates with PRMT1, and inhibition of arginine methylation alters the nuclear localization of ATXN2L without affecting its localization to stress granules.\",\n      \"method\": \"Co-immunoprecipitation, in vivo methylation assay, methylation inhibition, immunofluorescence localization\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP and localization with functional consequence, single lab\",\n      \"pmids\": [\"25748791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Chromosomal translocation creates an ATXN2L–JAK2 fusion gene encoding a chimeric protein containing all ATXN2L domains fused to the JAK2 catalytic (tyrosine kinase) domain, predicted to cause constitutive JAK-STAT pathway activation.\",\n      \"method\": \"RNA-sequencing, RT-PCR, Sanger sequencing of fusion transcript\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — fusion transcript experimentally confirmed; constitutive activation inferred by analogy, not directly assayed\",\n      \"pmids\": [\"29262599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"EGF upregulates ATXN2L expression via PI3K/Akt signaling; ATXN2L promotes gastric cancer cell migration/invasion via epithelial-to-mesenchymal transition and mediates oxaliplatin resistance partly through suppression of reactive oxygen species production and apoptosis.\",\n      \"method\": \"siRNA knockdown, pathway inhibitor experiments, PI3K/Akt signaling assays, ROS measurement, apoptosis assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional readouts with KD and pathway inhibition, single lab\",\n      \"pmids\": [\"30787271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ATXN2L is essential for mid-gestational embryonic development in mice; CRISPR/Cas9 deletion of Atxn2l exons 5–8 causes homozygous lethality with brain lamination defects, apoptosis, and increased multinucleated giant cells in fibroblasts. ATXN2L depletion does not dysregulate ATXN2, nor vice versa.\",\n      \"method\": \"CRISPR/Cas9 knockout, embryonic histology, cell biology (multinucleated cell analysis), genetic epistasis\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo KO with multiple phenotypic readouts and genetic epistasis, replicated across developmental stages\",\n      \"pmids\": [\"32698485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HDAC3 interacts with ATXN2L (shown by co-immunoprecipitation and LC-MS/MS) and recruits it to antagonize the NRG1-ErbB2-PI3K-AKT signaling axis in Schwann cells, thereby regulating myelination.\",\n      \"method\": \"Co-immunoprecipitation, liquid chromatography-mass spectrometry/MS, functional myelination assays in vivo\",\n      \"journal\": \"Phytotherapy research : PTR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — Co-IP and MS confirmed interaction, functional context established but mechanistic detail limited to single lab\",\n      \"pmids\": [\"36218239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ATXN2L primarily interacts with NUFIP2 and a broad set of RNA-binding proteins (PABPN1, MCRIP2, RBMS1, LARP1, PTBP1, FMR1, HNRNPK, SFPQ, CSDE1, etc.) as well as actin complex components (SYNE2, LMOD1, ACTA2). Absence of ATXN2L leads to depletion of NUFIP2 and SYNE2, while oxidative stress modulates specific interactions (increases HNRNPK, decreases SYNE2). In the SCA2 mouse model, NUFIP2 homodimers and SYNE1 accumulate in spinal cord, suggesting sequestration of ATXN2L interactors into ATXN2 aggregates.\",\n      \"method\": \"Co-immunoprecipitation in wild-type and ATXN2L-null fibroblasts, mass spectrometry proteome profiling, SCA2 knock-in mouse model\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reciprocal Co-IP combined with null-cell MS proteomics and in vivo disease model, multiple orthogonal methods\",\n      \"pmids\": [\"40220918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Conditional knockout of ATXN2L Lsm/LsmAD/PAM2 domains in CamK2a+ frontal cortex neurons reduces spontaneous horizontal movement and causes dysregulation of the alternative splicing pathway, indicating a role for ATXN2L's Like-Sm domains in splice regulation despite the protein's perinuclear location.\",\n      \"method\": \"Conditional CamK2a-CreERT2 loxP knockout, behavioral testing, global proteome profiling of frontal cortex\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with behavioral and proteomic phenotypes, single lab\",\n      \"pmids\": [\"41090760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ATXN2L undergoes liquid-liquid phase separation (LLPS) to form granules that recruit eukaryotic initiation factors (eIFs) and promote mRNA translation of targets such as ADAM9; this activity is further enhanced by co-localization with stress granules. Knockout of Atxn2l in mice suppresses hepatocellular carcinoma progression.\",\n      \"method\": \"LLPS assays, knockdown/knockout in HCC cells and mice, eIF co-localization, translation reporter assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — LLPS demonstrated with functional translation readout and in vivo KO, single lab\",\n      \"pmids\": [\"41273724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ATXN2L is found in cytoplasmic RNA granules (HERALDs) formed during heat stress recovery, where it associates with HSATIII RNA-derived MEWNG-rich proteins, actin filaments, and stress granule components.\",\n      \"method\": \"Immunofluorescence, RNA granule fractionation, protein complex identification (co-localization/pulldown implied)\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — preprint, single lab, co-localization without detailed mechanistic dissection of ATXN2L's specific role\",\n      \"pmids\": [\"bio_10.1101_2025.11.12.688122\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"ATXN2L is a perinuclear/cytoplasmic RNA-binding protein with Like-Sm (Lsm/LsmAD) and PAM2 domains that is essential for embryonic development; it undergoes liquid-liquid phase separation to form granules that recruit eIF translation factors and promote mRNA translation, interacts primarily with NUFIP2 and a broad network of RNA-binding and actin-complex proteins for RNA granule trafficking and surveillance, is asymmetrically dimethylated by PRMT1 which controls its nuclear localization, and regulates alternative splicing in neurons—with its dysregulation implicated in cancer invasiveness, chemoresistance (via EGF/PI3K/Akt signaling), and neurodegeneration through sequestration into ATXN2 polyQ aggregates.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2015,\n      \"finding\": \"ATXN2L is asymmetrically dimethylated in vivo and associates with protein arginine-N-methyltransferase 1 (PRMT1). Inhibition of arginine methylation alters the nuclear localization of ATXN2L, but neither mutation of the arginine-glycine-rich motifs nor methylation inhibition affects ATXN2L localization to stress granules, indicating that arginine methylation by PRMT1 controls ATXN2L nuclear (but not stress granule) localization.\",\n      \"method\": \"Co-immunoprecipitation, methylation inhibition assays, site-directed mutagenesis of RG motifs, immunofluorescence localization\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — reciprocal association shown by Co-IP, functional consequence of methylation on localization demonstrated, single lab\",\n      \"pmids\": [\"25748791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A chromosomal translocation t(9;13;16) in cutaneous CD4+ T-cell lymphoma fuses ATXN2L (chromosome 16p11) to JAK2 (chromosome 9p24), producing an ATXN2L–JAK2 chimeric protein that retains all ATXN2L domains fused to the JAK2 catalytic tyrosine kinase domain, predicted to cause constitutive JAK-STAT pathway activation.\",\n      \"method\": \"RNA sequencing, RT-PCR, Sanger sequencing of fusion transcript\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — fusion transcript verified by orthogonal sequencing methods; functional consequence inferred by analogy to other JAK2 fusions, single case study\",\n      \"pmids\": [\"29262599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ATXN2L promotes gastric cancer cell migration and invasion via epithelial-to-mesenchymal transition and confers intrinsic and acquired resistance to oxaliplatin by reducing reactive oxygen species and apoptosis. EGF upregulates ATXN2L expression through PI3K/Akt signaling, and oxaliplatin treatment itself induces ATXN2L expression and stress granule assembly.\",\n      \"method\": \"siRNA knockdown, invasion/migration assays, ROS measurement, apoptosis assays, generation of oxaliplatin-resistant cell strains, pharmacological PI3K/Akt inhibition, EGFR blocking\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multiple functional assays in cell lines with defined phenotypic readouts, single lab\",\n      \"pmids\": [\"30787271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ATXN2L is essential for embryonic development: homozygous CRISPR/Cas9 deletion of Atxn2l exons 5–8 in mice causes mid-gestational lethality with brain lamination defects and apoptosis, while heterozygotes are phenotypically normal over 12 months. ATXN2L-null mouse embryonic fibroblasts show increased multinucleated giant cells. ATXN2L and its paralog ATXN2 do not regulate each other's expression levels.\",\n      \"method\": \"CRISPR/Cas9 knockout mice, embryo histology, MEF culture, western blotting, locomotor assessment of heterozygotes\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic KO with strong embryonic lethality phenotype, histological and cellular characterization, replicated across developmental timepoints\",\n      \"pmids\": [\"32698485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HDAC3 interacts with ATXN2L and through this interaction antagonizes the NRG1-ErbB2-PI3K-AKT signaling axis in Schwann cells to suppress myelination. Inhibiting HDAC3's recruitment of ATXN2L (by jatrorrhizine treatment) restores myelination in diabetic peripheral neuropathy mice.\",\n      \"method\": \"LC-MS/MS proteomics, co-immunoprecipitation, in vivo db/db mouse model, nerve histopathology, nerve conduction velocity measurement\",\n      \"journal\": \"Phytotherapy research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP confirms HDAC3–ATXN2L interaction, in vivo phenotypic rescue data, single lab\",\n      \"pmids\": [\"36218239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ATXN2L's primary interactor is NUFIP2, with additional strong associations to RNA-binding proteins (PABPN1, MCRIP2, RBMS1, LARP1, PTBP1, FMR1, RPS20, FUBP3, MBNL2, ZMAT3, SFPQ, CSDE1, HNRNPK, HNRNPDL) and actin complex components (SYNE2, LMOD1, ACTA2, FYB, GOLGA3). ATXN2L absence leads to depletion of NUFIP2 and SYNE2 in fibroblasts. Oxidative stress increases HNRNPK but decreases SYNE2 association with ATXN2L, reflecting stress granule relocalization. In an SCA2 mouse model (Atxn2-CAG100-KnockIn), NUFIP2 homodimers and SYNE1 accumulate during ATXN2 aggregation, suggesting ATXN2L sequestration contributes to disease.\",\n      \"method\": \"Co-immunoprecipitation in WT and ATXN2L-null MEFs, mass spectrometry proteome profiling, SCA2 knock-in mouse spinal cord analysis\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — systematic Co-IP combined with proteome-wide MS profiling in null cells and disease mouse model; multiple orthogonal methods\",\n      \"pmids\": [\"40220918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Conditional deletion of ATXN2L Lsm/LsmAD/PAM2 domains (exons 10–17) in CamK2a+ frontal cortex neurons reduces spontaneous horizontal movement without causing neuronal death, and proteome profiling reveals dysregulation enriched in the alternative splicing pathway, suggesting ATXN2L's Lsm/LsmAD domains contribute to splice regulation from a perinuclear location.\",\n      \"method\": \"Conditional CamK2a-CreERT2 × floxed ATXN2L mice, tamoxifen induction, open-field locomotor testing, global proteome profiling by mass spectrometry\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — domain-specific conditional KO with behavioral and proteome-level functional readouts, single lab\",\n      \"pmids\": [\"41090760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ATXN2L undergoes liquid-liquid phase separation (LLPS) to form cytoplasmic granules that recruit eukaryotic initiation factors (eIFs) and promote mRNA translation of targets such as ADAM9 (ADAM metallopeptidase domain 9), thereby driving hepatocellular carcinoma progression. Co-localization with stress granules further enhances ATXN2L granule-mediated ADAM9 translation. Knockout of Atxn2l in mice suppresses HCC progression.\",\n      \"method\": \"LLPS assay, granule imaging, eIF co-localization, ADAM9 translation assays, ATXN2L knockdown/knockout in cell lines and mice, in vivo HCC models\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic LLPS characterization with in vitro and in vivo validation, single lab\",\n      \"pmids\": [\"41273724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ATXN2L-containing stress granule proteins (including ATXN2L itself) associate with MEWNG-rich proteins translated from cytoplasmic HSATIII lncRNAs during thermal stress recovery, placing ATXN2L in a cytoplasmic granule complex that also contains HSPA8 and ZC3HAV1.\",\n      \"method\": \"Proximity labeling, co-immunoprecipitation, fluorescence imaging, ribosome profiling (preprint)\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — preprint; ATXN2L is one component among many, single lab, not yet peer-reviewed\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"ATXN2L is a perinuclear RNA-binding protein with Lsm/LsmAD/PAM2 domains that is essential for embryonic development, undergoes liquid-liquid phase separation to form granules that promote mRNA translation, participates in RNA quality control and alternative splicing, is asymmetrically dimethylated by PRMT1 (controlling its nuclear but not stress-granule localization), primarily interacts with NUFIP2 and a broad network of RNA-binding proteins and actin complex components, can be oncogenically activated via ATXN2L–JAK2 chromosomal fusion, and is upregulated downstream of EGF/PI3K/Akt signaling to promote cancer cell invasiveness and chemoresistance.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ATXN2L is a cytoplasmic/perinuclear RNA-binding protein that undergoes liquid-liquid phase separation to form granules that recruit eukaryotic initiation factors and promote mRNA translation, and that regulates alternative splicing in neurons through its Lsm/LsmAD and PAM2 domains [PMID:41273724, PMID:41090760]. It primarily interacts with NUFIP2 and a broad network of RNA-binding proteins (PABPN1, LARP1, FMR1, PTBP1, SFPQ, HNRNPK) and actin-complex components (SYNE2, ACTA2), with oxidative stress dynamically remodeling these interactions; in SCA2 disease models, ATXN2L interactors such as NUFIP2 and SYNE1 are sequestered into ATXN2 polyglutamine aggregates [PMID:40220918]. ATXN2L is essential for mouse embryonic development, as homozygous deletion causes mid-gestational lethality with brain lamination defects and cytokinesis failure [PMID:32698485]. PRMT1-mediated asymmetric dimethylation controls its nuclear localization [PMID:25748791], and EGF/PI3K/Akt signaling upregulates ATXN2L expression, through which it promotes epithelial-to-mesenchymal transition, cancer cell invasion, and chemoresistance [PMID:30787271].\",\n  \"teleology\": [\n    {\n      \"year\": 2015,\n      \"claim\": \"Establishing how ATXN2L subcellular distribution is regulated: PRMT1-mediated asymmetric arginine dimethylation was shown to control nuclear versus cytoplasmic localization of ATXN2L, independently of its stress granule association.\",\n      \"evidence\": \"Co-immunoprecipitation, in vivo methylation assay, and immunofluorescence after methylation inhibitor treatment in cultured cells\",\n      \"pmids\": [\"25748791\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Specific arginine residues targeted by PRMT1 were not mapped\",\n        \"Functional consequence of nuclear vs. cytoplasmic partitioning on RNA metabolism was not tested\",\n        \"Single-lab study without independent confirmation\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Discovery of an ATXN2L–JAK2 fusion oncogene demonstrated that ATXN2L can serve as a translocation partner that contributes structural domains to aberrant signaling kinases in hematological malignancy.\",\n      \"evidence\": \"RNA-seq, RT-PCR, and Sanger sequencing of a fusion transcript in a patient sample\",\n      \"pmids\": [\"29262599\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Constitutive JAK-STAT activation by the fusion was inferred by analogy, not directly demonstrated\",\n        \"Contribution of ATXN2L domains to fusion protein localization or stability was not assessed\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Connecting ATXN2L to growth-factor signaling and cancer: EGF/PI3K/Akt signaling was shown to upregulate ATXN2L, which in turn promotes EMT, invasion, and chemoresistance by suppressing ROS and apoptosis in gastric cancer cells.\",\n      \"evidence\": \"siRNA knockdown, PI3K/Akt pathway inhibitors, ROS measurement, apoptosis assays in gastric cancer cell lines\",\n      \"pmids\": [\"30787271\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Molecular targets of ATXN2L that mediate ROS suppression were not identified\",\n        \"In vivo validation of the chemoresistance phenotype was not provided\",\n        \"Single-lab study\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrating essential developmental function: CRISPR/Cas9 knockout of Atxn2l in mice established that ATXN2L is required for mid-gestational viability, proper brain lamination, and cytokinesis, while showing functional independence from the paralog ATXN2.\",\n      \"evidence\": \"CRISPR/Cas9 germline knockout, embryonic histology across developmental stages, multinucleated cell quantification, genetic epistasis with Atxn2\",\n      \"pmids\": [\"32698485\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The molecular mechanism by which ATXN2L loss leads to cytokinesis defects and brain lamination failure was not resolved\",\n        \"Cell-type-specific contributions to the embryonic lethal phenotype remain unclear\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linking ATXN2L to myelination regulation: HDAC3 was shown to recruit ATXN2L to antagonize the NRG1-ErbB2-PI3K-AKT signaling axis in Schwann cells.\",\n      \"evidence\": \"Co-immunoprecipitation, LC-MS/MS interaction discovery, in vivo myelination assays\",\n      \"pmids\": [\"36218239\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"The direct mechanism by which ATXN2L antagonizes NRG1-ErbB2 signaling was not dissected\",\n        \"Published in a phytotherapy journal with limited mechanistic follow-up\",\n        \"Single-lab study without independent replication\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defining the ATXN2L interactome and its disease relevance: comprehensive proteomics in wild-type and null cells identified NUFIP2 as the primary partner and revealed that loss of ATXN2L depletes NUFIP2 and SYNE2; in SCA2 mice, ATXN2L interactors accumulate in spinal cord, establishing a sequestration mechanism for polyQ neurodegeneration.\",\n      \"evidence\": \"Reciprocal Co-IP in WT and ATXN2L-null fibroblasts, quantitative MS proteomics, SCA2 knock-in mouse spinal cord analysis\",\n      \"pmids\": [\"40220918\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether ATXN2L sequestration into ATXN2 aggregates is directly pathogenic or a secondary consequence is unresolved\",\n        \"RNA targets co-regulated by the ATXN2L–NUFIP2 complex remain unidentified\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Establishing a neuron-specific splicing function: conditional deletion of ATXN2L's Lsm/LsmAD/PAM2 domains in forebrain neurons caused locomotor deficits and dysregulated alternative splicing, attributing RNA processing activity to these domains despite ATXN2L's predominantly perinuclear localization.\",\n      \"evidence\": \"CamK2a-CreERT2 conditional knockout, behavioral testing, global proteomics of frontal cortex\",\n      \"pmids\": [\"41090760\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether ATXN2L directly binds pre-mRNAs or acts indirectly through splicing factor interactions was not resolved\",\n        \"Single-lab study; splicing changes characterized at the proteome, not transcriptome level\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Revealing a translation-promoting mechanism via phase separation: ATXN2L undergoes LLPS to form cytoplasmic granules that recruit eIF translation initiation factors and enhance mRNA translation of targets including ADAM9, with Atxn2l knockout suppressing hepatocellular carcinoma in vivo.\",\n      \"evidence\": \"In vitro LLPS assays, eIF co-localization, translation reporter assays, Atxn2l knockout in HCC mouse models\",\n      \"pmids\": [\"41273724\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"The biophysical determinants driving ATXN2L phase separation (IDRs, RNA valence) were not fully characterized\",\n        \"Genome-wide identification of translationally regulated mRNA targets is lacking\",\n        \"Single-lab study\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the full catalog of mRNA targets whose translation or splicing is directly regulated by ATXN2L; the structural basis of ATXN2L phase separation and how it is modulated by post-translational modifications; and whether ATXN2L sequestration into polyQ aggregates is a primary pathogenic driver in SCA2 or a downstream consequence.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No transcriptome-wide CLIP or ribosome profiling data for ATXN2L RNA targets\",\n        \"No structural model of ATXN2L or its condensates\",\n        \"Causal role of ATXN2L loss-of-function in SCA2 pathogenesis remains untested\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [5, 6, 7]},\n      {\"term_id\": \"GO:0045182\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 5, 7, 8]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [5, 6, 7]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 4]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"NUFIP2\",\n      \"PRMT1\",\n      \"SYNE2\",\n      \"HDAC3\",\n      \"LARP1\",\n      \"FMR1\",\n      \"HNRNPK\",\n      \"SFPQ\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"ATXN2L is a perinuclear RNA-binding protein containing Lsm, LsmAD, and PAM2 domains that is essential for mammalian embryonic development, with homozygous loss causing mid-gestational lethality with brain lamination defects [PMID:32698485]. ATXN2L undergoes liquid–liquid phase separation to form cytoplasmic granules that recruit eukaryotic initiation factors and promote mRNA translation, and it participates in alternative splicing regulation through its Lsm/LsmAD domains [PMID:41273724, PMID:41090760]. Its primary physical interactor is NUFIP2, and it associates with a broad network of RNA-binding proteins and actin complex components; oxidative stress dynamically remodels these interactions as ATXN2L relocalizes to stress granules [PMID:40220918]. ATXN2L is asymmetrically dimethylated by PRMT1, which controls its nuclear but not stress-granule localization, and its expression is upregulated by EGF/PI3K/Akt signaling to promote cancer cell invasiveness and chemoresistance [PMID:25748791, PMID:30787271].\",\n  \"teleology\": [\n    {\n      \"year\": 2015,\n      \"claim\": \"The first post-translational regulatory mechanism for ATXN2L was defined: PRMT1-mediated asymmetric arginine dimethylation controls ATXN2L nuclear localization but is dispensable for its recruitment to stress granules, establishing that distinct signals govern ATXN2L's dual compartmentalization.\",\n      \"evidence\": \"Co-IP, methylation inhibition, RG-motif mutagenesis, and immunofluorescence in cultured cells\",\n      \"pmids\": [\"25748791\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Nuclear functions of ATXN2L remain undefined\",\n        \"Whether other PRMTs modify ATXN2L is untested\",\n        \"Single-lab observation without independent replication\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Discovery of an ATXN2L–JAK2 fusion transcript in cutaneous T-cell lymphoma demonstrated that ATXN2L can serve as a 5′ partner in oncogenic chromosomal rearrangements, analogous to other JAK2 fusions that constitutively activate JAK-STAT signaling.\",\n      \"evidence\": \"RNA-seq, RT-PCR, and Sanger sequencing of a t(9;13;16) translocation in a single patient\",\n      \"pmids\": [\"29262599\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Constitutive kinase activity of the fusion was inferred by analogy, not directly demonstrated\",\n        \"Single case report; frequency of ATXN2L–JAK2 fusions unknown\",\n        \"Mechanism by which ATXN2L domains contribute to oncogenic activity is uncharacterized\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"ATXN2L was placed in the EGF/PI3K/Akt signaling axis as a downstream effector that promotes epithelial–mesenchymal transition, cell invasion, and chemoresistance in gastric cancer, revealing a cancer-relevant function beyond its RNA-binding roles.\",\n      \"evidence\": \"siRNA knockdown, invasion/migration assays, ROS and apoptosis measurement, oxaliplatin-resistant cell generation, PI3K/Akt inhibition in gastric cancer cell lines\",\n      \"pmids\": [\"30787271\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direct transcriptional or post-transcriptional targets mediating chemoresistance are not identified\",\n        \"In vivo validation in tumor models was not performed\",\n        \"Mechanism linking stress granule assembly to oxaliplatin resistance is unclear\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Genetic ablation of Atxn2l in mice established its essentiality for embryonic development, with homozygous loss causing mid-gestational lethality, brain lamination defects, and increased multinucleated cell formation, distinguishing it functionally from its paralog ATXN2.\",\n      \"evidence\": \"CRISPR/Cas9 whole-body knockout mice, embryo histology across developmental stages, MEF culture, western blotting\",\n      \"pmids\": [\"32698485\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Molecular pathways driving embryonic lethality are not delineated\",\n        \"Cell-type-specific requirements during development are unknown\",\n        \"Cause of multinucleated cell phenotype (cytokinesis failure vs. cell fusion) is unresolved\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"The HDAC3–ATXN2L interaction was identified as a negative regulator of NRG1-ErbB2-PI3K-AKT myelination signaling in Schwann cells, placing ATXN2L in a chromatin-associated regulatory complex relevant to peripheral neuropathy.\",\n      \"evidence\": \"LC-MS/MS proteomics, Co-IP, in vivo db/db diabetic mouse model with nerve histopathology and conduction velocity\",\n      \"pmids\": [\"36218239\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether ATXN2L acts as an HDAC3 co-repressor or scaffold is not determined\",\n        \"Direct gene targets of the HDAC3–ATXN2L complex are uncharacterized\",\n        \"Single-lab finding without independent confirmation\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Systematic interactome mapping identified NUFIP2 as ATXN2L's primary binding partner and revealed a broad network of RNA-binding proteins and actin complex components; stress-dependent remodeling of these interactions linked ATXN2L to stress granule biology and, in an SCA2 mouse model, suggested that ATXN2 aggregation sequesters ATXN2L-associated factors.\",\n      \"evidence\": \"Co-IP/MS in WT and ATXN2L-null MEFs, SCA2 Atxn2-CAG100-KnockIn mouse spinal cord proteomics\",\n      \"pmids\": [\"40220918\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct RNA targets bound by ATXN2L are not defined\",\n        \"Whether ATXN2L sequestration causally contributes to SCA2 pathogenesis is unproven\",\n        \"Structural basis of the ATXN2L–NUFIP2 interaction is unknown\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Conditional deletion of ATXN2L's Lsm/LsmAD/PAM2 domains in cortical neurons demonstrated a requirement for these domains in normal locomotor behavior and implicated ATXN2L in alternative splicing regulation based on proteome-level changes.\",\n      \"evidence\": \"CamK2a-CreERT2 conditional KO mice, open-field locomotor testing, global proteome profiling by MS\",\n      \"pmids\": [\"41090760\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Specific splice targets are not identified\",\n        \"Contribution of individual domains (Lsm vs. PAM2) was not dissected\",\n        \"Only proteome-level enrichment inferred; direct splicing assays were not performed\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"ATXN2L was shown to undergo liquid–liquid phase separation forming cytoplasmic granules that recruit eIF complexes to promote mRNA translation of specific targets such as ADAM9, directly linking ATXN2L's condensation behavior to translational control and hepatocellular carcinoma progression.\",\n      \"evidence\": \"LLPS assays, granule imaging with eIF co-localization, ADAM9 translation assays, ATXN2L KO in mice with in vivo HCC models\",\n      \"pmids\": [\"41273724\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Transcriptome-wide identification of ATXN2L-granule-regulated mRNAs is lacking\",\n        \"Biophysical determinants of phase separation (IDRs, multivalency) not fully mapped\",\n        \"Whether LLPS is required for all ATXN2L translational functions or specific subsets is unclear\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include the full repertoire of direct RNA targets, the structural basis of ATXN2L phase separation and NUFIP2 binding, the mechanism by which ATXN2L loss causes embryonic lethality, and whether ATXN2L sequestration is a causal contributor to SCA2 neurodegeneration.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No CLIP-seq or equivalent data defining direct RNA targets\",\n        \"No high-resolution structure of ATXN2L or its complexes\",\n        \"Causal role of ATXN2L in SCA2 pathogenesis untested by genetic rescue\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [5, 6, 7]},\n      {\"term_id\": \"GO:0045182\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 7, 8]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [5, 6, 7]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [6, 7]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 4]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"NUFIP2\",\n      \"PRMT1\",\n      \"HDAC3\",\n      \"PABPN1\",\n      \"LARP1\",\n      \"FMR1\",\n      \"SYNE2\",\n      \"HNRNPK\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}